Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2016 | Challenges of drug repurposing

Robert Coleman • 6 Nov 2016
NCRI 2016
Breast Cancer

Robert Coleman, MBBS, MD, FRCP, FRCPE of Sheffield Cancer Research, University of Sheffield, UK discusses issues with drug repurposing. Most drug development is supported by the pharmaceutical industry for commercial reasons, which is rarely possible for drug repurposing. Promising drugs are not licensed in the indication and clinicians cannot prescribe bisphosphonates without a licence. Dr Coleman highlights the case of bisphosphonates, which are used to treat osteoporosis and have a very powerful effect on breast cancer recurrence in postmenopausal women. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.

More from Robert Coleman

Trial updates in breast cancer from ASCO: TAILORx, PAKT, MONARCH 2 & MONALEESA-3
2:45
Trial updates in breast cancer from ASCO: TAILORx, PAKT, MONARCH 2 & MONALEESA-3
Robert Coleman • 1 Jun 2018
Early breast cancer treatment: denosumab
3:27
Early breast cancer treatment: denosumab
Robert Coleman • 1 Jun 2018
PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
1:56
PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
Robert Coleman • 1 Jun 2018
Next steps for drug re-purposing
1:25
Next steps for drug re-purposing
Robert Coleman • 6 Nov 2016

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals